SOSV

Pear Bio uses organ-on-a-chip and computer vision technology to recreate, visualize, and compute the human tumor microenvironment and its effects on cancer progression. The company was founded in 2017 and is headquartered in London.

Pear Bio uses organ-on-a-chip and computer vision technology to recreate, visualize, and compute the human tumor microenvironment and its effects on cancer progression. The company was founded in 2017 and is headquartered in London.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcare system. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring. Phable is marching onward to impact a billion lives over the next 5 years.

The Quantumcyte team is a highly talented group of biology and high tech commercialization experts with experience in academic, biotech, diagnostics, medical device and high tech organizations including Stanford, Intel, Thermo Fisher, Johnson and Johnson, Genentech and others. They are driven to ensure scalability and manufacturability of their products. To meet the basic research needs they have forged very close relationships and collaborations with experts in the field of cancer and genomic sequencing.

VemiCo is a biotechnology company.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

Pear Bio uses organ-on-a-chip and computer vision technology to recreate, visualize, and compute the human tumor microenvironment and its effects on cancer progression. The company was founded in 2017 and is headquartered in London.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

The Quantumcyte team is a highly talented group of biology and high tech commercialization experts with experience in academic, biotech, diagnostics, medical device and high tech organizations including Stanford, Intel, Thermo Fisher, Johnson and Johnson, Genentech and others. They are driven to ensure scalability and manufacturability of their products. To meet the basic research needs they have forged very close relationships and collaborations with experts in the field of cancer and genomic sequencing.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Gypsy Bay Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Gypsy Bay Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcare system. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring. Phable is marching onward to impact a billion lives over the next 5 years.

Developing hardware for manufacturing next-generation medicines.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Developing hardware for manufacturing next-generation medicines.

Pear Bio uses organ-on-a-chip and computer vision technology to recreate, visualize, and compute the human tumor microenvironment and its effects on cancer progression. The company was founded in 2017 and is headquartered in London.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

VemiCo is a biotechnology company.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcare system. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring. Phable is marching onward to impact a billion lives over the next 5 years.

Nanopath is a bi-tech startup.

The Quantumcyte team is a highly talented group of biology and high tech commercialization experts with experience in academic, biotech, diagnostics, medical device and high tech organizations including Stanford, Intel, Thermo Fisher, Johnson and Johnson, Genentech and others. They are driven to ensure scalability and manufacturability of their products. To meet the basic research needs they have forged very close relationships and collaborations with experts in the field of cancer and genomic sequencing.

Bioptamers, Inc. specializes in the development of cellular and gene therapies aimed at treating cancer. Founded in 2018 and headquartered in New Castle, Delaware, with an additional office in São Paulo, Brazil, the company focuses on innovative therapeutic delivery technologies using monoclonal antibodies and antibody-drug conjugates. Bioptamers is creating a platform to optimize aptamer selection, allowing for personalized cancer therapy tailored to individual patient needs. The company aims to transform these specialized molecules into valuable clinical products, which will be licensed to pharmaceutical companies for further development and commercialization.

11 Biomics LLC develops biological therapeutics for the cannabis industry. It offers small and large scale treatment and protection against fungal and bacterial diseases in cannabis and hemp. The company is based in Albuquerque, New Mexico.

Saana is a Healthcare Technology company built for chronic illness patients to empower them to fight back. Based on their patients' conditions, smart technology, the latest science & expert recommendations, they deliver personalized meals & wellness solutions to improve their quality of life and strengthen their immunity.

The Quantumcyte team is a highly talented group of biology and high tech commercialization experts with experience in academic, biotech, diagnostics, medical device and high tech organizations including Stanford, Intel, Thermo Fisher, Johnson and Johnson, Genentech and others. They are driven to ensure scalability and manufacturability of their products. To meet the basic research needs they have forged very close relationships and collaborations with experts in the field of cancer and genomic sequencing.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Biomimetic Solutions develops clean meat tissue engineering technology, and a three dimensional (3D) matrices for cell culture which optimizes the process and makes the process of cell development more suitable. Additionally, it develops scaffolds for regenerative medicine field, toxicological in-vitro tests, and pharmaceutical industry for clinical tests. The company was founded in 2016 and is based in Nova Lima, Brazil.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

Galactica Biotech Limited, founded in 2017 and based in Cork, Ireland, specializes in developing artificial intelligence-based solutions for drug design, machine learning, and systems biology. The company focuses on drug repurposing, utilizing its technology to identify new applications for existing molecules in both market and development phases. This innovative approach aims to discover treatments for major and orphan diseases, thereby reducing risks for patients and minimizing time and costs for pharmaceutical companies.

The Quantumcyte team is a highly talented group of biology and high tech commercialization experts with experience in academic, biotech, diagnostics, medical device and high tech organizations including Stanford, Intel, Thermo Fisher, Johnson and Johnson, Genentech and others. They are driven to ensure scalability and manufacturability of their products. To meet the basic research needs they have forged very close relationships and collaborations with experts in the field of cancer and genomic sequencing.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Biomimetic Solutions develops clean meat tissue engineering technology, and a three dimensional (3D) matrices for cell culture which optimizes the process and makes the process of cell development more suitable. Additionally, it develops scaffolds for regenerative medicine field, toxicological in-vitro tests, and pharmaceutical industry for clinical tests. The company was founded in 2016 and is based in Nova Lima, Brazil.

BlueTurtleBio Technologies creates a next generation therapeutic using a patent pending platform technology. The company's mission is the golden triangle of healthcare: safety, effectiveness and affordability. Most healthcare options miss one or more of these standards. At Blue Turtle, they plan to recruit a genetically malleable and easily replenishable organ in the human body: the microbiome.

Specifiko Business Consulting operates a video news and English-learning platform specifically designed for healthcare and pharmaceutical professionals and students in Japan and China. The platform offers access to over 2,000 industry-specific news videos, which include full transcripts and translations to facilitate comprehension for non-native English speakers. Specifiko provides its services in two tiers: a free version that delivers real-time news content and a subscription model that offers a comprehensive language learning experience. The subscription service features an interactive database with more than 50,000 individually-translated healthcare and pharmaceutical terms, aimed at enhancing English proficiency through various language-acquisition modules. The team behind Specifiko consists of professionals from China, Japan, and Western countries, bringing together 30 years of combined expertise in the pharmaceutical industry and language education. The company is headquartered in Shanghai, China.

Specifiko Business Consulting operates a video news and English-learning platform specifically designed for healthcare and pharmaceutical professionals and students in Japan and China. The platform offers access to over 2,000 industry-specific news videos, which include full transcripts and translations to facilitate comprehension for non-native English speakers. Specifiko provides its services in two tiers: a free version that delivers real-time news content and a subscription model that offers a comprehensive language learning experience. The subscription service features an interactive database with more than 50,000 individually-translated healthcare and pharmaceutical terms, aimed at enhancing English proficiency through various language-acquisition modules. The team behind Specifiko consists of professionals from China, Japan, and Western countries, bringing together 30 years of combined expertise in the pharmaceutical industry and language education. The company is headquartered in Shanghai, China.

BlueTurtleBio Technologies creates a next generation therapeutic using a patent pending platform technology. The company's mission is the golden triangle of healthcare: safety, effectiveness and affordability. Most healthcare options miss one or more of these standards. At Blue Turtle, they plan to recruit a genetically malleable and easily replenishable organ in the human body: the microbiome.

Specifiko Business Consulting operates a video news and English-learning platform specifically designed for healthcare and pharmaceutical professionals and students in Japan and China. The platform offers access to over 2,000 industry-specific news videos, which include full transcripts and translations to facilitate comprehension for non-native English speakers. Specifiko provides its services in two tiers: a free version that delivers real-time news content and a subscription model that offers a comprehensive language learning experience. The subscription service features an interactive database with more than 50,000 individually-translated healthcare and pharmaceutical terms, aimed at enhancing English proficiency through various language-acquisition modules. The team behind Specifiko consists of professionals from China, Japan, and Western countries, bringing together 30 years of combined expertise in the pharmaceutical industry and language education. The company is headquartered in Shanghai, China.

BBB Technologies Inc. is a mobile healthcare technology company based in Mountain View, California, with additional offices in Seoul, South Korea, and Shenzhen, China. Founded in 2014, the company focuses on developing innovative devices and applications that facilitate early-stage diagnosis and enhance treatment decisions. Its flagship product, the Elemark, is an Android-powered mobile blood diagnostic device capable of testing over 50 medical conditions within 2 to 60 seconds using just a single drop of blood. This device is complemented by an integrated service platform that provides actionable insights for researchers, doctors, and patients globally. BBB Technologies aims to ensure equal access to medical services and treatments, reflecting its commitment to improving healthcare outcomes. The company has received recognition through various awards, including winning competitions at TechCrunch events in Seoul and New York, as well as accolades from Tech in Asia.